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ABSTRACT 
 
Objectives: Mevalonate kinase deficiency (MKD) is a rare metabolic disease characterized 
by recurrent inflammatory episodes. This study aims to describe the genetic and phenotypic 
characteristics and the response to treatment in an international cohort of MKD patients. 
 
Methods: MKD cases were extracted from the Eurofever registry (EAHC Project No. 
2007332), an international, multicentre registry that retrospectively collects data on children 
and adults suffering from periodic fevers. We analysed cases that had been genetically or 
biochemically validated. 
 
Results: One hundred and fourteen patients were included in this study. The median age of 
onset was 0.5 years. Patients had on average 12 episodes per year. Most patients had 
gastrointestinal symptoms (n=112), mucocutaneous involvement (n=99), lymphadenopathy 
(n=96) or musculoskeletal symptoms (n=89). Neurological complaints included headache 
(n=43), but also cerebellar syndrome (n=2), mental retardation (n=4) and seizures (n=6). AA-
amyloidosis was noted in six patients. Macrophage activation syndrome arose in one patient. 
Between attacks patients were generally well, but over one third of patients suffered from 
constitutional symptoms, such as fatigue, between febrile attacks. Patients with combined 
p.V377I/p.I268T heterozygosity suffered significantly more often from AA-amyloidosis. 
Patients without p.V377I mutation suffered more often from severe musculoskeletal 
involvement. 
Treatment with NSAIDs can relieve symptoms. Steroids given during attacks, anakinra and 
etanercept appear to improve symptoms and can induce complete remission in MKD 
patients.  
 
Conclusion: This study describes the clinical and genetic characteristics of 114 MKD 
patients, which is the largest cohort so far. The clinical manifestations confirm earlier reports. 
However, the prevalence of AA-amyloidosis was higher than expected.  
 
 
 
 
 
 
 
 
  
INTRODUCTION 
Mevalonate kinase deficiency (MKD) is a rare autoinflammatory syndrome characterized by 
fever and generalized inflammation. The disease encompasses a continuum of two 
phenotypes, known as the Hyper Immunoglobulinemia D and periodic fever syndrome 
(HIDS, MIM#260920) and Mevalonic Aciduria (MA, MIM#610377).[1-3] Patients suffering 
from MKD present with fever, gastrointestinal complaints, lymphadenopathy, arthralgia, 
myalgia, skin rash and mucosal ulcers. Furthermore, patients suffering from the more severe 
phenotype Mevalonic Aciduria can also experience dysmorphic features, pre- and postnatal 
growth retardation and neurological and ocular involvement.[4]  
Both phenotypes are caused by mutations in the mevalonate kinase (MVK) gene.[5] This 
gene encodes mevalonate kinase, an enzyme that is part of the mevalonate pathway. This 
pathway produces cholesterol and unsaturated lipid chains, known as non-sterol 
isoprenoids.[6] Activity of mevalonate kinase is reduced in MKD patients, varying from 1.8% 
to 28% in patients with the HIDS phenotype to below 0.5% in patients affected by the MA 
phenotype, although overlap occurs.[5,7,8] The substrate of this enzyme, mevalonic acid, 
accumulates and is excreted in the urine. Patients suffering from MKD therefore often 
excrete elevated amounts of mevalonic acid.[8-12] Due to the lack of clinical criteria, patients 
can only be diagnosed by the identification of two pathogenic MVK mutations or by detection 
of decreased enzyme activity.[13] 
The first MKD patients were described in 1984.[2] Currently, just several hundred patients 
with this rare disease are known. It has been more frequently reported in patients with a 
Caucasian ethnicity; a disproportionate number of Dutch HIDS patients have been described. 
This is probably caused by a founder mutation (p.V377I) in the Dutch population.[14] The 
current number of MKD patients is certainly an underestimate as many patients will not be 
diagnosed with MKD.[6] As many physicians are still not familiar with this disease, the 
diagnostic delay is currently 7.1 years.[15] MKD patients are often suspected of many other 
diseases (e.g. infections, immunodeficiency or other autoinflammatory syndromes) before 
being diagnosed correctly.[15] 
This study aims to describe the clinical and genetic characteristics and the response to 
treatment in a large, international cohort, in order to increase knowledge about this rare 
disease and hence facilitate diagnosis and inform the discussion on treatment and prognosis 
with affected families. 
METHODS 
All patients were enrolled in the Eurofever registry (EAHC Project No. 2007332), an 
international, multicentre registry that retrospectively collects information on patients 
suffering from periodic fever. Patients were enrolled since November 2009.[16] 
Epidemiological, demographic and clinical data were collected anonymously by local 
physicians. Independent ethical committee approval for enrolling patients was granted in 
accordance with local requirements. Written informed consent was obtained from patients 
according to local ethical regulations. Two experts on MKD (AS and JF) checked all enrolled 
patients on genetic, biochemical and clinical characteristics. For this analysis, all cases 
enrolled until November 2014 were included. Patients harbouring two MVK mutations or 
harbouring one mutation in combination with an abnormal metabolic study result were 
considered as true MKD patients. These metabolic studies were either measurement of 
raised urinary mevalonic acid or reduced mevalonate kinase enzyme activity in leukocytes or 
fibroblasts.  
 
Statistics  
All analyses were performed using Statistical Package for the Social Sciences (SPSS) 21. 
Categorical variables were described as frequencies and percentages. Median and 
interquartile ranges (IQR) were used to describe numerical variables. To determine a 
genotype-phenotype relation, differences in clinical features between groups with specific 
genotypes were analysed using Fisher’s exact test. A p-value <0.05 was considered to be 
statistically significant. 
 
RESULTS 
Demographic data 
In November 2014, 161 patients had been enrolled by their local physicians in the Eurofever 
registry with a diagnosis of MKD. Nineteen of these patients were excluded because genetic 
testing had not been performed, no MVK mutations were found, or clinical data were 
incomplete. Another 28 patients with one mutation were excluded as MKD could not be 
confirmed by demonstration of decreased mevalonate kinase activity or elevated urinary 
mevalonic acid excretion (figure 1). 
A total of 114 patients (53 male, 61 female) were entered by 31 centres from twelve 
countries. The majority of these patients was born in Italy (n=31) and Netherlands (n = 28) 
(figure 2A). The median age of onset was 6 months (IQR 9 weeks to 19 months). The 
median age at diagnosis was 6.5 years (IQR 3.5-14.7) (figure 2B). Thus, the median 
diagnostic delay was six years (IQR 1.9-14.2 years) (figure 2C). The median follow-up period 
of this study was 11.5 years.  
Figure 1. Flowchart of included patients 
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Figure 2. Characteristics of 114 MKD patients 
 
A. Country of birth of 114 MKD patients. The numbers in brackets indicate the number of patients. Other countries 
included Albania, Australia, Cyprus, Czech Republic, Morocco, Russia and Turkey. B. Age at onset of 114 MKD 
patients. The numbers in brackets indicate the number of patients. C. Diagnostic delay according to the year of 
birth. D. The genotype of all patients. The numbers in brackets indicate the number of patients. 
Genetic characteristics  
Complete gene screening was performed in 47 (41%) patients, whereas in 46 (40%) patients 
only the most relevant exons were sequenced. In four (4%) patients only the most relevant 
point mutations were screened. Ninety-six patients harboured at least one p.V377I mutation 
(84%), fourteen of them had a homozygous p.V377I mutation (12%). The second most 
frequent mutation was p.I268T, occurring in 29 patients (25%). None of them were 
homozygous (figure 2D). 
Three mutations are not present in the Infevers database.[17] A rare mutation was found in 
one patient: p.C152Y. This patient also had a p.V377I mutation and had a mild clinical 
pattern, as no musculoskeletal and neurological manifestations were reported. As this 
mutation was not known to be pathogenic, enzyme activity in both fibroblasts and leukocytes 
was performed, showing decreased activity in both assays.  
Further, a 447^448insGCCTAC mutation, which is not known to be pathogenic, was found in 
one patient who also had a p.V377I mutation. This patient was not severely affected, 
suffering mostly from gastrointestinal symptoms, myalgia and lymphadenopathy. Metabolic 
studies were not performed. 
One patient with a mild phenotype had a TGA-CGA mutation. This patient also had a 
p.R388X mutation. 
Clinical characteristics 
Ninety-nine of 114 patients suffered from recurrent disease episodes, while six patients 
suffered from a chronic disease and nine patients had a chronic course with exacerbations. 
Most patients had an episode duration of five days and suffered from twelve episodes per 
year (figure 3A, 3B). Febrile episodes were provoked by specific triggers in 51 patients, 
mainly by vaccination (n=38), stress (n=26) and infection (n=18) (figure 3C).  
Most frequent MKD symptoms 
All clinical features are summarized in table 1. Seventy-nine patients had constitutional 
symptoms, such as malaise (n=70), weight loss (n=67), fatigue (n=69) and mood disorders 
(n=23). In 23% of the patients, malaise was seen independent of fever, while fatigue 
occurred independent of fever in 35% of them. Mood disorders were mentioned independent 
of fever in 25% of patients. 
One-hundred and twelve patients had gastrointestinal complaints. Most of them experienced 
abdominal pain (n=98), diarrhoea (n=93) and vomiting (n=76). In four patients the recurrent 
sterile inflammation had led to abdominal adhesions.  
Ninety-nine patients suffered from mucocutaneous symptoms, such as aphthous stomatitis 
(n=67) and pharyngitis (n=31). Fifteen percent of patients had aphthous stomatitis 
irrespective of fever. Maculopapular rash (n=43) and urticarial rash (n=16) were seen only 
during febrile episodes in 92% and 62%, respectively.  
Most patients (n=102) had lymphadenopathy, which was usually, but not exclusively cervical 
(n=96) and tender (n=59). Generalized lymphadenopathy occurred in a sizeable minority 
(n=30). 
Musculoskeletal symptoms were noted in 89 patients. Most had myalgia (n=64) and 
arthralgia (n=80), specifically during fever episodes (85% and 82%). Arthritis was less 
common (n=31).  
Severe manifestations 
Patients with severe manifestations are mentioned in table 2 and some of them are 
discussed in greater detail below.  
Eleven patients had severe neurological manifestations, namely seizures (n=6), cerebellar 
syndrome (n=2) and mental retardation (n=4). One patient with a heterozygous p.A334T and 
c.421dupG (A141fs) mutation, who suffered from a recurrent disease, experienced both a 
cerebellar syndrome and mild mental retardation. This patient also had retinitis pigmentosa 
and has been described before as a case report.[18] Another patient who suffered from a 
cerebellar syndrome also had a recurrent disease. He was p.V377I homozygous and was 
diagnosed with type 1 Arnold Chiari cerebellar syndrome by an incidental finding upon a 
brain MRI performed at the age of two years; hence the relationship between this cerebellar 
syndrome and MKD is not clear. Despite this malformation, he showed normal psychomotor 
development. He had a twin who died in utero. One patient with mental retardation was 
heterozygous for p.I268T and p.P165L and had a colitis as part of the MKD. The two other 
patients with mental retardation were both mildly affected concerning the other features.  
Five patients suffered from severe musculoskeletal involvement: flexion contractures (n=5), 
bone erosion (n=2), osteolytic lesions (n=2) and bone deformity (n=1). One patient with a 
homozygous p.H20Q mutation suffered from severe polyarthtritis with involvement of all 
joints. The inflammation led to contractures and bone deformity. Two brothers, who had a 
heterozygous p.H20N and p.R215Q mutation, had flexion contractures, bone erosion and 
osteolytic lesions. The older brother had involvement of two joints. The younger brother, who 
suffered from a continuous disease based on clinical features and chronic elevation of 
inflammatory parameters, had involvement of thirteen joints. The first contractures occurred 
at the age of two years.  
Macrophage activation syndrome arose in one patient, who had a heterozygous p.V377I and 
IVS7-1G>C mutation. Six patients suffered from AA-amyloidosis. One patient had a p.V377I 
mutation in combination with a p.S272F mutation. The other five patients were compound 
heterozygous for the p.V377I mutation and the p.I268T mutation. One of these five had a 
continuous disease course and deceased around the age of nineteen years. The other five 
patients with amyloidosis suffered from a recurrent disease.  
Three patients with reported continuous disease had no other severe manifestations. One 
patient, who was heterozygous for p.T237S and p.I268T, had died due to acute respiratory 
distress syndrome before the age of one year.  
Figure 3. Features of inflammatory attacks in 108 MKD patients. 
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A. Episode duration in days. B. Frequency of the number of episodes per year. C. Triggers in 51 MKD patients. 
Other triggers include cold (n=4); exercise (n=5); trauma (n=2); food (n=1); menstruation (n=4); fatigue (n=6); 
travel (n=1).  
 
 
 
 
          
 
 
 
Table 1. Clinical characteristics of 114 MKD patients 
 
      n   % during + % during++  
every episode fever only 
Disease pattern 
   Recurrent     99   (87%)  
   Chronic with exacerbations  9   (8%) 
   Chronic     6   (5%) 
Constitutional symptoms*   79/111   (71%)  
   Malaise     70/108   (65%) 53%  77% 
   Fatigue     69/109   (63%) 52%  65% 
   Mood disorders    23/95     (24%)  43%  75% 
   Weight loss     16/102   (16%)  
Mucocutaneous involvement   99/113   (87%) 
   Aphthous stomatitis    67/111   (60%) 37%  85% 
   Maculopapular rash   43/111   (39%) 21%  92% 
   Urticarial rash    16/109   (15%) 38%  62% 
   Exudative pharyngitis   31/109   (28%) 16%  90% 
Musculoskeletal involvement   89/113   (79%) 
   Arthralgia     80/113   (71%) 34%  85% 
   Myalgia     64/112   (57%) 34%  82% 
   Arthritis     31/109   (28%) 24%  87% 
   Severe musculoskeletal involvement** 5/110    (5%) 
Gastrointestinal symptoms   112/114 (98%) 
   Abdominal pain    98/111   (88%) 44%  84% 
   Diarrhoea     93/111   (84%) 38%  89% 
   Vomiting     76/110   (69%) 29%  82% 
Ocular involvement    17/113   (15%) 
   Conjunctivitis    11/113   (10%) 9%  64% 
   Uveitis     2/113   (2%) 
   Impaired vision     2/113   (2%) 
   Cataract     3/113   (3%) 
Neurological involvement   46/114   (41%) 
   Headache      43/114   (38%) 40%  67% 
   Severe neurological involvement*** 11/114   (10%) 
Lymphoid organs    102/113 (90%) 
   Generalized enlargement   39/103   (38%) 36%  78% 
   Cervical lymphadenopathy   96/113   (85%) 64%  85% 
   Painful lymph nodes    59/99   (60%) 42%  88% 
 
The denominator varies as missing values are disregarded in this table. The percentage is taken from the 
number of known values.  
*Constitutional symptoms were defined as fever, malaise, fatigue, mood disorders or weight loss.  
**Severe musculoskeletal involvement was defined as flexion contractures, bone deformity, bone erosion or 
osteolytic lesion.  
***Severe neurological involvement was defined as seizures, cerebellar syndrome or mental retardation.  
+During every episode means that the symptom was present during every febrile episode. 
++During fever only means that the symptom was only present during febrile episodes and not in between.  
  
Table 2. Severely affected patients 
Pati
ent 
Mutation 1 Mutation 
2 
age at 
onset 
(years) 
epis
ode 
dura
tion 
(day
s) 
disease 
course  
Amyloid
osis 
Se
izu
re
s 
Cere
bella
r 
synd
rom
e 
Ment
al 
retar
dati
on 
Flexi
on 
cont
ract
ures 
Os
teo
lyti
c 
les
ion 
Bon
e 
eros
ion 
Bon
e 
defo
rmit
y 
MAS Treatment with biologicals 
1 p.V377I p.I268T 0.12  x continuous  x          
2 p.V377I p.I268T 4 not 
know
n 
recurrent x systemic        
3 p.V377I p.I268T 4 10 recurrent x systemic       partial response on anakinra maintenance 
4 p.V377I p.S272F 3 13 recurrent x         partial response on anakinra maintenance 
5 p.V377I p.I268T 1 7 recurrent x systemic       partial response on etancercept  
6 p.V377I p.I268T 2.06 6 recurrent x         partial response on anakinra used during attacks,  
partial response on etanercept  
7 p.H20Q p.H20Q 0.16 4 recurrent     x   x  Partial response on etanercept  
8 p.H20N p.R215Q 0.08 5 recurrent     x x x   complete response on anakinra maintenance, 
 partial etanercept 
9 p.H20N p.R215Q 0  continuous    x x x   partial response anakinra,  
fail on etanercept 
10 p.V377I  p.L265R  0.26 6 continuous 
and 
recurrent 
    x      
11 p.V310L p.V310L 3 x continuous     x     partial response on anakinra maintenance 
12 p.V377I p.V377I 0.04 3 recurrent  x         
13 p.V377I p.I268T 0.22 5 recurrent  x        complete response on anakinra used during attacks and as  
maintenance therapy 
14 p.V377I p.V377I 0.14 5 recurrent  x         
15 p.V377I p.S272F 0.5 9 continuous  
and recurrent 
x        complete  response on anakinra maintenance, fail on  
etanercept, complete response on canakinumab 
16 p.V377I c.790del
C 
0.03 5 recurrent  x         
17 p.V377I p.I268T 0.32 >20 recurrent  x         
18 p.A334T p.A141fs  0.01 4 recurrent   x x      fail on anakinra maintenance 
19 p.V377I  p.V377I  0.5 4 recurrent   x        
20 p.V377I  c.606ins
G 
0.34 3 recurrent    x       
21 p.V377I p.I268T 0.62 5 recurrent    x       
22 p.P165L p.I268T 0.33 no 
speci
fic 
patte
rn 
recurrent    x      Partial response on anakinra used during attacks 
23 p.V377I IVS7-
1G>C 
2 5 recurrent         x partial response anakinra used during attacks and as  
maintenance therapy 
24 p.P165L p.I268T 0 x continuous          partial response on anakinra maintenance, fail on etanercept 
25 p.V310L p.V310L 3.33 x continuous           
26 p.T237S p.I268T 0.01 x continuous           
 
 
  
 
Laboratory findings 
Abnormal immunoglobulin (Ig) D  levels were found in 55 of 76 tested patients. Other 
immunoglobulin levels were also measured: IgA was elevated in 48 of 90 patients, while IgG 
was elevated in fourteen of 91 tested patients. Immunoglobulin M was within normal range in 
the majority of the 91 tested patients.  
Measurement of urinary mevalonic acid was performed in 40 patients; 37 of them showed 
elevated excretion. Thus, three patients excreted normal amounts of mevalonic acid. All 
three of them suffered from typical MKD symptoms. The first patient was homozygous for 
p.V377I and had a confirmed impairment of mevalonate kinase enzyme activity. Urine was 
collected during a febrile episode. The second patient was compound heterozygous for 
p.R388X and TGA-CGA stop codon. In this patient mevalonic acid was measured as part of 
the whole organic acid screening. The last patient was compound heterozygous for p.V377I 
and p.V310M and had a mild clinical pattern. In this patient urine was not collected during 
fever.  
Enzymatic studies in both leukocytes and fibroblasts were performed in 19 patients. Reduced 
mevalonate kinase enzyme activity in fibroblasts was found in seven of eight tested patients, 
while fifteen of sixteen tested patients showed reduced enzyme activity in leukocytes. 
Unexpectedly, one patient with a homozygous p.V377I mutation, typical MKD symptoms and 
elevated urinary mevalonic acid excretion reported normal enzyme activity in both fibroblasts 
and leukocytes. 
Associations between the genotype and phenotype 
To analyse genotype-phenotype associations, we divided all patients into four groups: 
homozygous p.V377I, combined heterozygous p.V377I and p.I268T, patients with one p.V77I 
mutation and another second mutation than p.V377I or p.I268T and patients without a 
p.V377I mutation. The frequency of MKD features were compared between the groups. Five 
out of 25 patients with p.V377I/p.I268T combined heterozygosity experienced amyloidosis as 
compared to 1 out of 89 patients with other genotypes (p=0.01). Further, patients without a 
p.V377I mutation suffered more often from a chronic course, musculoskeletal and severe 
musculoskeletal involvement (table 3).  
 
Table 3. Associations between the genotype and clinical characteristics 
 
 
Genotype/  p.V377I+ p.V377I+ p.V377I+ patients without p-value 
phenotype  p.V377I (n=14) p.I268T (n=25) other (n=57) p.V377I (n=18) 
 
Chronic course  0%  4%  0%  28%  0.000 
Family history  45%  38%  29%  53%  ns 
Constitutional   85%  68%  85%  89%  ns 
symptoms   
 
Mucocutaneous  100%   76%  91%  78%  ns 
involvement   
 
Gastrointestinal  100%  96%  100%  94%  ns 
involvement   
 
Lymphoid  93%  92%  89%  89%  ns 
involvement  
  
Ocular    21%  8%  11%  35%  ns 
involvement   
 
Neurological   64%  48%  30%  47%  ns 
involvement   
 
Severe neurological 21%  12%  5%  11%   ns 
involvement 
 
Musculoskeletal  86%  64%  77%   100%  0.025 
involvement  
     
Severe musculoskeletal 0%  0%  2%  22%  0.006 
Involvement 
 
Amyloidosis  0%  20%  2%  0%  0.01 
Patients were compared with patients from the other groups regarding the clinical variables, using Fisher 
exact test. A p-value <0.05 was considered to be significant.  
 
Treatment 
NSAIDS 
Non-steroidal anti-inflammatory drugs (NSAIDs) were used in 66 patients, usually to treat the 
symptoms of attacks, and were beneficial in 48 of them. Seven of these patients reported a 
complete response to NSAIDs. Five of them used NSAIDs during attacks only and not as 
maintenance therapy. Two of them used NSAIDs as monotherapy, the other five in 
combination with corticosteroids. The response to steroids was reported as complete in four 
of them and as partial in one.   
Corticosteroids 
Corticosteroids were used by 49 patients to treat fever attacks. Nineteen of them reported 
complete suppression of inflammatory episodes (16/19 had not used biologics) and 21 
patients had some improvement. Five out of seven patients who used maintenance 
corticosteroids reported some benefit, failure was noted in the other two. 
Colchicine and statins 
Colchicine was used by 21 patients; thirteen of them did not respond to this treatment and 
only one patient with p.V377I/p.S135L heterozygosity had a complete response. 
Mediterranean Fever (MEFV) screening had not been performed in this Caucasian patient 
from Italy. This patient did not use NSAIDs, steroids or biologics. Statins were used in fifteen 
patients; in eleven patients this treatment failed, moreover three of them reported worsening 
of their disease. Four patients noted some improvement of symptoms. 
Biologicals 
Anakinra was used only during attacks by eight patients, with three of them having a 
complete response and the other five a partial response. Nineteen patients used anakinra 
only as maintenance therapy, which led to complete remission in three of them and a partial 
response in thirteen. In three patients Anakinra was not effective. All three suffered from a 
recurrent disease. One of them was severely affected and suffered from cerebellar 
syndrome, mental retardation and retinitis pigmentosa. The two other patients were mildly 
affected.  
Five patients used canakinumab; four went in complete remission, while one had a partial 
response. The patient with a partial response was p.V377I/p.G338D heterozygous and had 
failed on NSAIDs, steroids, anakinra, etanercept and adalimumab, before the initiation of 
canakinumab. Etanercept had a beneficial effect in sixteen patients, of whom two had a 
complete response. Ten other patients failed to respond to etanercept.  
DISCUSSION 
This study describes the phenotypic and genotypic characteristics and the response to 
treatment in the largest cohort of MKD patients reported so far. Moreover, the vast majority of 
these patients have not been described in previous cohorts.[19] This large cohort enables us 
to give a broad description of the clinical features and treatment of this rare disease.  
 
In many respects, our study confirms the clinical characteristics reported by previous studies. 
Typically, the disease starts within the first year of life. Onset after the age of 4 years makes 
the diagnosis extremely unlikely. The most common symptoms were abdominal pain, 
diarrhoea, vomiting, lymphadenopathy, arthralgia, myalgia and aphthous stomatitis. Six 
patients suffered from AA-amyloidosis, which is almost double compared to previous cohorts. 
19] Only one patient in our cohort experienced a macrophage activation syndrome, which is 
less than described in the study of Bader-Meunier et al.[8] 
 
Unexpectedly, many patients had complaints between attacks. This concerned mainly 
constitutional symptoms such as fatigue, malaise and headache, but also oral aphthous 
ulcers. It has to be noted that these are also very common symptoms in the general 
population. Hence, a causal relation between mevalonate kinase deficiency and these 
symptoms remains uncertain. 
 
This study confirms previous findings that measurement of IgD is not a reliable method to 
diagnose MKD, as 28% of the tested patients in this cohort did not have elevated IgD 
levels.[13] Further, measurement of urinary mevalonic acid is a sensitive method for 
screening on MKD, as 93% of the tested patients excreted elevated amounts of mevalonic 
acid.[8] Unexpectedly, measurement of mevalonate kinase enzyme activity could be entirely 
normal in the presence of known pathogenic mutations and elevated urinary excretion of 
mevalonic acid. Enzymatic studies have been regarded as the diagnostic gold standard for 
mevalonate kinase deficiency.  
 
The most frequent combination of mutations was p.V377I/I268T heterozygosity occurring in 
22% of the patients, followed by p.V377I homozygosity in 12%. Patients with a combined 
heterozygosity for p.V377I/p.I268T suffered significantly more often from AA-amyloidosis.  
 
As reported previously, treatment with statins and colchicine was not effective in most 
patients.[19,20] Seventy-five percent of the patients reported at least some improvement of 
symptoms when using NSAIDs, but a complete effect is rarely seen. Corticosteroids are 
more effective to terminate inflammatory attacks, but long-term side effects are a major 
drawback. IL-1 blockade is beneficial in many MKD patients, but apparently not as effective 
as observed in the IL-1 driven cryopyrin-associated periodic syndromes, at least using the Il-
1 receptor antagonist (Anakinra).[20] Although the number of MKD patients reported here is 
substantially larger than that described in a previous paper on therapy in the Eurofever 
cohort, the findings on therapy remain essentially unchanged.[20] 
 
The retrospective design of the Eurofever registry comes with a number of limitations. Due to 
this design, there are quite some missing values, which might have induced a bias. The 
missing values might cause an underrepresentation as the symptoms might have been 
present. For that reason, we have chosen to use the number of known values as 
denominator in the tables. Further, the Eurofever Registry collects data on patients suffering 
from periodic fever. The participating physicians are (paediatric) immunologists and 
(paediatric) rheumatologists.  As mevalonic aciduria patients experience predominantly 
neurological symptoms, these patients are more likely to be seen by a (paediatric) 
neurologist or a specialist in metabolic diseases.  Therefore, some of the more severely 
affected MKD patients may not have been enrolled. Besides, mevalonic aciduria patients 
may be underrepresented as they are more likely to die at a young age.[21] Still, our cohort 
included some patients who can be classified as MA. A limitation to the interpretation of 
therapeutic interventions is the absence of criteria for complete and partial response. Bias is 
inevitable due to the lack of control groups and randomization. Furthermore, as it is unknown 
whether drugs were used simultaneously or solely, it is even more difficult to draw solid 
conclusions about the efficacy of treatments. However, the Eurofever registry does provide 
information on current practice.  
 
In conclusion, we describe the clinical and genetic features in the largest, international cohort 
of MKD patients. Most MKD patients suffer from fever, accompanied by gastrointestinal 
symptoms, lymphadenopathy, arthralgia and aphthous stomatitis. AA-amyloidosis (5%) and 
macrophage activation syndrome (0.8%) are rare, but severe complications of MKD. Patients 
can benefit from treatment with NSAIDs, steroids and biologicals, mainly anakinra and 
etanercept. Statins and colchicine are usually not effective in MKD patients.  
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